title: Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulin.
abstract: Galactomannan is an insoluble polysaccharide that has been shown to reduce postprandial excursions. We assessed the impact of a novel galactomannan derivative (PAZ320) on the magnitude of 2-hour postprandial glucose excursions in individuals with type 2 diabetes who were being treated with oral medication and/or insulin. Investigators recently reported findings from a single-center, open-label, prospective study that evaluated the efficacy of PAZ320 in 24 subjects with type 2 diabetes who were treated with oral antidiabetic agents and/or insulin. End points included adverse events and area under the curve during 3-hour postprandial glucose excursion (gAUC). Subjects consumed a test meal without PAZ320 at baseline and then ingested low-dose (8 g) and high-dose (16 g) PAZ320 with test meals at subsequent intervention visits. A post hoc analysis was conducted to determine changes in 2-hour postprandial glucose excursions. Among the 20 subjects for whom data were available for all clinic visit test meals, 15 (75%) responded to low-dose, high-dose, or both medication dosages. Low-dose responders (n = 8) experienced clinically significant improvements in 2-hour postprandial glucose excursions from baseline excursions compared with nonresponders (-28.00 ± 25.97 mg/dL vs 23.42 ± 11.45 mg/dL, P = .005). Similar differences were seen in high-dose responders (-28.82 ± 24.26 vs 33.89 ± 20.56 mg/dL, P < .0001). PAZ320 was shown to be safe in all patients studied and effective in controlling postprandial glucose in a large portion of the study population. Additional studies are needed to determine its long-term effects on HbA1c and to further define which subpopulation(s) may respond to PAZ320 therapy.
authors.affiliation: Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Department of Medicine, Section of Endocrinology, Lebanon, NH.
authors.forename: Laura E
authors.initials: LE
authors.lastname: Trask
authors.affiliation: Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Department of Medicine, Section of Endocrinology, Lebanon, NH.
authors.forename: Sushela S
authors.initials: SS
authors.lastname: Chaidarun
authors.affiliation: Boston Therapeutics, Inc, Manchester, NH, USA.
authors.forename: David
authors.initials: D
authors.lastname: Platt
authors.affiliation: CGParkin Communications, Inc, Boulder City, NV, USA chris@cgparkin.org.
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Parkin
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D008351:Mannans / Q000627:therapeutic use*; D008875:Middle Aged; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D008351:Mannans; C000598421:PAZ320; C012990:galactomannan; D005690:Galactose
keywords: HbA1c; galactomannan; glucose excursion; postprandial glucose; type 2 diabetes